9783319235578-3319235575-Nonclinical Statistics for Pharmaceutical and Biotechnology Industries (Statistics for Biology and Health)

Nonclinical Statistics for Pharmaceutical and Biotechnology Industries (Statistics for Biology and Health)

ISBN-13: 9783319235578
ISBN-10: 3319235575
Edition: 1st ed. 2016
Author: Max Kuhn, Lanju Zhang, Ian Peers, Stan Altan
Publication date: 2016
Publisher: Springer
Format: Hardcover 720 pages
FREE US shipping
Buy

From $41.70

Book details

ISBN-13: 9783319235578
ISBN-10: 3319235575
Edition: 1st ed. 2016
Author: Max Kuhn, Lanju Zhang, Ian Peers, Stan Altan
Publication date: 2016
Publisher: Springer
Format: Hardcover 720 pages

Summary

Nonclinical Statistics for Pharmaceutical and Biotechnology Industries (Statistics for Biology and Health) (ISBN-13: 9783319235578 and ISBN-10: 3319235575), written by authors Max Kuhn, Lanju Zhang, Ian Peers, Stan Altan, was published by Springer in 2016. With an overall rating of 3.5 stars, it's a notable title among other Biology (Biological Sciences) books. You can easily purchase or rent Nonclinical Statistics for Pharmaceutical and Biotechnology Industries (Statistics for Biology and Health) (Hardcover) from BooksRun, along with many other new and used Biology books and textbooks. And, if you're looking to sell your copy, our current buyback offer is $2.32.

Description

This book serves as a reference text for regulatory, industry and academic statisticians and also a handy manual for entry level Statisticians. Additionally it aims to stimulate academic interest in the field of Nonclinical Statistics and promote this as an important discipline in its own right. This text brings together for the first time in a single volume a comprehensive survey of methods important to the nonclinical science areas within the pharmaceutical and biotechnology industries. Specifically the Discovery and Translational sciences, the Safety/Toxiology sciences, and the Chemistry, Manufacturing and Controls sciences. Drug discovery and development is a long and costly process. Most decisions in the drug development process are made with incomplete information. The data is rife with uncertainties and hence risky by nature. This is therefore the purview of Statistics. As such, this book aims to introduce readers to important statistical thinking and its application in these nonclinical areas. The chapters provide as appropriate, a scientific background to the topic, relevant regulatory guidance, current statistical practice, and further research directions.

Rate this book Rate this book

We would LOVE it if you could help us and other readers by reviewing the book